Similarly, CDH1 and PIK3CA have been commonly identified in invasive lobular breast carcinoma [29], but whether these concurrent mutations are sensitive to PI3K/Akt/mTOR agents remains to be confirmed. This evidence concerns the gene CDH1 and invasive lobular breast carcinoma.